Literature DB >> 26687137

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

Sergey V Silkin1, Sergey S Startsev1, Marina E Krasnova1, Grigory A Raskin2, Natalia V Mitiushkina3, Aglaya G Iyevleva3,4, Anna P Sokolenko3,4, Evgeny N Imyanitov5,6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26687137     DOI： 10.1007/s12029-015-9792-2

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  11 in total

1.  Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma.

Authors:  Finn Ole Larsen; Dan Taksony Solyom Hoegdall; Estrid Hoegdall; Dorte Nielsen
Journal:  Acta Oncol       Date:  2015-09-12       Impact factor: 4.089

2.  Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Authors:  Rona Yaeger; Andrea Cercek; Eileen M O'Reilly; Diane L Reidy; Nancy Kemeny; Tamar Wolinsky; Marinela Capanu; Marc J Gollub; Neal Rosen; Michael F Berger; Mario E Lacouture; Efsevia Vakiani; Leonard B Saltz
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

3.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

4.  A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.

Authors:  P M Sanz-Altamira; E O'Reilly; K E Stuart; L Raeburn; C Steger; N E Kemeny; L B Saltz
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

Review 5.  Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.

Authors:  N Schweitzer; A Vogel
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-02-19       Impact factor: 3.043

6.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

7.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

8.  Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

Authors:  T André; H Blons; M Mabro; B Chibaudel; J-B Bachet; C Tournigand; M Bennamoun; P Artru; S Nguyen; C Ebenezer; N Aissat; A Cayre; F Penault-Llorca; P Laurent-Puig; A de Gramont
Journal:  Ann Oncol       Date:  2012-10-05       Impact factor: 32.976

9.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

10.  BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Authors:  Benjamin Goeppert; Lena Frauenschuh; Marcus Renner; Stephanie Roessler; Albrecht Stenzinger; Frederick Klauschen; Arne Warth; Monika Nadja Vogel; Arianeb Mehrabi; Mohammadreza Hafezi; Katja Boehmer; Andreas von Deimling; Peter Schirmacher; Wilko Weichert; David Capper
Journal:  Mod Pathol       Date:  2013-12-06       Impact factor: 7.842
View more
  5 in total

1.  Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

Authors:  Judit Kocsis; Anita Árokszállási; Csilla András; Ingrid Balogh; Edit Béres; Júlia Déri; István Peták; Levente Jánváry; Zsolt Horváth
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Authors:  Audra N Boscoe; Catherine Rolland; Robin Kate Kelley
Journal:  J Gastrointest Oncol       Date:  2019-08

Review 3.  Molecular Diagnostics in Clinical Oncology.

Authors:  Anna P Sokolenko; Evgeny N Imyanitov
Journal:  Front Mol Biosci       Date:  2018-08-27

Review 4.  Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

Authors:  Svetlana N Aleksakhina; Evgeny N Imyanitov
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

Review 5.  Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Authors:  Alice Boilève; Marc Hilmi; Matthieu Delaye; Annemilaï Tijeras-Raballand; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.